The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Rituximab: Mechanism of Action
Open accessAbstract
Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its undeniable therapeutic value, we still do not fully understand the mechanisms of action responsible for rituximab's anti-tumor effects. Direct signaling, complement dependent cellular cytotoxicity and antibody dependent cellular cytotoxicity all appear to play a role in rituximab efficacy. In vitro, animal model and clinical data addressing each of these mechanisms of action are reviewed, as are data speaking to the complexity of interactions between these mechanisms. Taken together, these data suggest different mechanisms are likely important in different scenarios. Study of the complex mechanisms of action that contribute to the clinical efficacy of rituximab have led to novel clinical trials including novel combinations, schedules, and generation of additional antibodies designed to have even greater effect. Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable approach to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Rubenstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7311 · Cited by 327
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
C1q, Autoimmunity and Apoptosis
BOTTO, M. (2002) · Immunobiology · doi:10.1078/0171-2985-00141 · Cited by 289
Treon, S. P., Hansen, M., Branagan, A. R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S. R., Touroutoglou, N., Turnbull, B., Anderson, K. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.059 · Cited by 263
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Harjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256
Czuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., & Hernandez-Ilizaliturri, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1254 · Cited by 232
Bowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Self-citationPedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 210
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
Wooldridge, J. E., Ballas, Z., Krieg, A. M., & Weiner, G. J. (1997) · Blood · doi:10.1182/blood.v89.8.2994 · Cited by 203
Self-citationEgeblad, M., Ewald, A. J., Askautrud, H. A., Truitt, M. L., Welm, B. E., Bainbridge, E., Peeters, G., Krummel, M. F., & Werb, Z. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000596 · Cited by 199
Wang, S.-Y., Racila, E., Taylor, R. P., & Weiner, G. J. (2008) · Blood · doi:10.1182/blood-2007-02-074716 · Cited by 194
Self-citationHernandez‐Ilizaliturri, F. J., Jupudy, V., Ostberg, J. R., Oflazoglu, E., Huberman, A., Repasky, E. A., & Czuczman, M. S. (2003) · PubMed · Cited by 188
Beers, S. A., Chan, C. H. T., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., & Glennie, M. J. (2008) · Blood · doi:10.1182/blood-2008-04-149161 · Cited by 180
Bannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D., Reed, J. C., & Byrd, J. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.012 · Cited by 178
Zhou, X., Hu, W., & Qin, X. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0089 · Cited by 178
The complement system in B cell regulation
CARROLL, M. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.03.017 · Cited by 177
Jazirehi, A. R., Vega, M. I., & Bonavida, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2184 · Cited by 167
Flieger, D., Renoth, S., Beier, I., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1693 · Cited by 166
Racila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Self-citationSchliemann, C., Palumbo, A., Zuberbühler, K., Villa, A., Kaspar, M., Trachsel, E., Klapper, W., Menssen, H. D., & Neri, D. (2008) · Blood · doi:10.1182/blood-2008-05-160747 · Cited by 150
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
Bowles, J. A., & Weiner, G. J. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.06.018 · Cited by 148
Self-citationWang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 143
Self-citationFriedberg, J. W., Neuberg, D. S., Gribben, J. G., Fisher, D. C., Canning, C. M., Koval, M. A., Poor, C. M., Green, L. M., Daley, J. F., Soiffer, R. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03535.x · Cited by 140
Golay, J., Cittera, E., Gaetano, N. D., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., & Introna, M. (2006) · PubMed · Cited by 129
Stockmeyer, B., Dechant, M., van Egmond, M., Tutt, A. L., Sundarapandiyan, K., Graziano, R. F., Repp, R., Kalden, J. R., Gramatzki, M., Glennie, M. J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5954 · Cited by 121
Lefebvre, M.-L., Krause, S. W., Salcedo, M., & Nardin, A. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000203081.43235.d7 · Cited by 111
Jazirehi, A. R., Gan, X.-H., de Vos, S., Emmanouilides, C. E., & Bonavida, B. (2003) · PubMed · Cited by 111
Leonard, J. P., Link, B. K., Emmanouilides, C. E., Gregory, S. A., Weisdorf, D. J., Andrey, J., Hainsworth, J. D., Sparano, J. A., Tsai, D. E., Horning, S. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0815 · Cited by 108
Self-citationStolz, C., Heß, G., Hähnel, P. S., Grabellus, F., Hoffarth, S., Schmid, K. W., & Schüler, M. (2008) · Blood · doi:10.1182/blood-2007-11-124487 · Cited by 104
Beum, P. V., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2916 · Cited by 100
Carlotti, E., Palumbo, G. A., Oldani, E., Tibullo, D., Salmoiraghi, S., Rossi, A., Golay, J., Pulsoni, A., Foà, R., & Rambaldi, A. (2007) · Haematologica · doi:10.3324/haematol.11288 · Cited by 96
Robak, T. (2009) · PubMed · Cited by 87
The high‐affinity FcγRI on PMN: regulation of expression and signal transduction
Hoffmeyer, F., Witte, K. K., & Schmidt, R. E. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00381.x · Cited by 76
Vega, M. I., Huerta‐Yépez, S., Martinez-Paniagua, M. A., Martínez-Miguel, B., Hernández‐Pando, R., González-Bonilla, C. R., Chinn, P. C., Hanna, N., Hariharan, K., Jazirehi, A. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1234 · Cited by 62
Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
Tawara, T., Hasegawa, K., Sugiura, Y., Harada, K., Miura, T., Hayashi, S., Tahara, T., Ishikawa, M., Yoshida, H., Kubo, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2294 · Cited by 56
Emmanouilides, C. E., Jazirehi, A. R., & Bonavida, B. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802320970226 · Cited by 45
In vivoModel of Follicular Lymphoma Resistant to Rituximab
Dalle, S., Dupire, S., Manquat, S. B., Reslan, L., Pleșa, A., & Dumontet, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1685 · Cited by 36
Klepfish, A., Schattner, A., Ghoti, H., & Rachmilewitz, E. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70106-7 · Cited by 36
Cited by
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Self-citationChen, D. S., Irving, B. A., & Hodi, F. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1362 · Cited by 654
Metadata
- Authors
- Weiner, G. J.
- Venue
- Seminars in Hematology
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 47
- Issue
- 2
- Pages
- 115-123
- ISSN
- 0037-1963 (ISSN-L)
- OpenAlex
- W2133205391
- Cited by
- 786
- References
- 65
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.